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Abstract
Background: Fibromyalgia is a syndrome with heterogeneous symptoms. The evaluation in the clinical setting
usually fails to cover the complexity of the syndrome. This study aims to determine how different aspects of
fibromyalgia are inter-related when measured by means of a self-reporting tool. The objective is to develop a more
complete evaluation model adjusted to the complexity and multi-dimensional nature of the syndrome.
Methods: Application was made of the Fibromyalgia Impact Questionnaire, the Hospital Anxiety and Depression
Scale, the Brief Pain Inventory, the Fatigue Assessment Scale, the Health Assessment Questionnaire, the General
Health Questionnaire (GHQ-28), the Chronic Pain Coping Inventory, the Arthritis Self-efficacy Scale and the Sleep
Quality Scale. An assessment was made, on the basis of clinical interviews, case histories and specific tests, of the
patient sociodemographic data, comorbidity, physical exploration and other clinical indexes. An exploratory factor
analysis was made, with comparisons of the clinical index scores in extreme groups of patients.
Results: The ICAF composed of 59 items was obtained, offering four factors that explain 64% of the variance, and
referred to as Emotional Factor (33.7%), Physical-Activity (15%), Active Coping (9%) and Passive Coping (6.3%). A t-
test between the extreme scores of these factors in the 301 patients revealed statistically significant differences in
occupational status, medically unexplained syndromes, number of tender points, the six-minutes walk test,
comorbidity and health care costs.
Conclusions: This study offers a tool allowing more complete and rapid evaluation of patients with fibromyalgia.
The test intrinsically evaluates the emotional aspects: anxiety and depression, and their impact upon social aspects.
It also evaluates patient functional capacity, fatigue, sleep quality, pain, and the way in which the patient copes
with the disease. This is achieved by means of a self-assessment questionnaire based on elements from well
known tests.
Background
Fibromyalgia is a syndrome with heterogeneous symp-
toms. The importance of each symptom has not been
fully established, though generalized skeletal muscle
pain, and particularly pain on digital palpation in certain
points is considered by the American College of Rheu-
matology (ACR) to constitute a diagnostic criterion [1].
The presence of sleep disturbances and other somatic
symptoms [2], together with emotional alterations [3],
define a clinical condition with an important impact
upon patient life [4]. In fact, fibromyalgia variably affects
patient behaviour in the context of daily life activities
and family, occupational and personal life, and in the
way the patient copes with the limitations imposed by
the disease [5].
The evaluation in the clinical setting usually fails to
cover the complexity of the syndrome. Use is generally
made of questionnaires such as the Fibromyalgia Impact
Questionnaire (FIQ) [6] to assess the impact of the dis-
ease, the Health Assessment Questionnaire (HAQ) [7]
for measuring functional capacity, questionnaires
addressing fatigue such as the Fatigue Assessment Scale
( F A S )[ 8 ] ,p a i ns c a l e ss u c ha st h eB r i e fP a i nI n v e n t o r y
(BPI) [9], and questionnaires for measuring anxiety,
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State-Trait-Anxiety Inventory (STAXI) [11], or for asses-
sing depression such as the Beck Depression Inventory
(BDI) [12] or the Center for Epidemiologic Studies
Depression-Scale (CES-D) [13]. Coping strategy tools
are also used, such as the Multidimensional Pain Inven-
tory (MPI) [14] or the Chronic Pain Coping Inventory
(CPCI) [15], as well as evaluations of self-efficacy expec-
tations in the form of the Arthritis Self-Efficacy Scale
(ASES) [16]. There are no specific data to indicate
which tools are most appropriate or which areas should
be explored. The evaluated domains are varied [17], and
in some cases redundant. In sum, in daily practice no
tool is able to offer a good evaluation of the degree of
patient impairment or of treatment efficacy. Likewise, to
date no evaluative battery involving a multivariate study
has been developed to address this task.
This study aims to determine how different aspects of
fibromyalgia are inter-related when measured by means
of a self-reporting tool. The objective is to develop a
more complete evaluation model adjusted to the com-
plexity and multi-dimensional nature of the syndrome.
In addition, the study aims to evaluate the usefulness of
the tool when contrasted with other information sources
external to the patient, such as physical examination or
different indexes showing the patient impairment.
Methods
The study population was primarily urban and com-
p r i s e dw o m e na n dm e na b o v e1 8y e a r so fa g ew i t ha
diagnosis of fibromyalgia according to ACR classification
criteria [1], recruited consecutively from 15 rheumatol-
ogy clinics throughout the country. Patients presenting
other concomitant diseases with severely impaired phy-
sical or functional capacity, rheumatic inflammatory dis-
eases, cardiovascular or pulmonary diseases with poor
aerobic capacity, uncontrolled psychiatric diseases,
patients involved in litigation process, and patients
included in any other clinical trial were excluded from
the study. A total of 301 patients with fibromyalgia were
included, 10 men and 291 women, with a mean age of
49 years.
In the first phase information was obtained throught a
face-to-face interview. In the second study phase in
which self-perceived health and psychosocial variables
were assessed, the patients were requested to complete
questionnaires, and a functional physical examination
was made.
The study protocol was approved by the Clinical
Research Ethics Committee of Gregorio Marañón Hos-
pital (Madrid, Spain).
Self-assessment questionnaires used
The questionnaires were selected from among those
most commonly used to evaluate symptoms of
fibromyalgia, and the principal variables related to this
syndrome. We also considered the use of length of
instruments to reduce the effort of the patients. The fol-
lowing questionnaires were used: FIQ [6,18,19]; Hospital
Anxiety and Depression Scale (HADs) [20,21]; BPI
[9,22]; FAS [8]; HAQ [7,23]; General Health Question-
naire (GHQ-28) [24]; CPCI [15]; ASES [25]; and a Sleep
Quality Scale (SQS) where 0 = very good and 10 = very
poor.
Although there are many questionnaires for evaluating
depression and anxiety, the HADS is considered useful
for evaluating fibromyalgia. Due to overlapping medical
and psychological symptoms of the illness, this question-
naire is more suitable, since it concentrates on evaluat-
ing the cognitive aspects of anxiety and depression [17],
and is a good screening test which is sensitive to change
[26].
Hetero-assessment and objective indexes
Information was obtained on the main sociodemo-
graphic variables, frequent clinical manifestations, their
intensity (scored by a Likert scale 1-4), the number of
medically unexplained syndromes (MUSs) and other
comorbidities, and the utilization of health care and
non-health care resources, laboral status and a stimated
cost of the fibromyalgia impact during the year before.
An evaluation was also made of patient physical condi-
tion based on the six-minutes walk test (6-MWT) [27];
the Lumbar Spine Flexion Test (LSFT) [28]; and the
Patient Global Passive Mobility Assessment (PGMA)
[19].
Statistical analysis
An individual analysis was made of each of the ques-
tionnaires, taking into account their original correcting
rules, along with a reliability study of the corresponding
scales and, where applicable, an exploration of the scales
obtained in our sample, based on exploratory factor ana-
lysis. The aim was to simplify and reduce the number of
items of each scale according to their internal consis-
tency and complementation with the global tools used.
With the resulting scales and items an exploratory fac-
tor analysis was made to determine grouping of the
information obtained from patients self-reports. Finally,
an evaluation was made of the usefulness of the scores
obtained with the new tool, in relation to other variables
obtained by hetero-assessment. Calculation was made of
the score obtained by each patient in relation to each of
the factors obtained. To this effect, the factorial score
calculation procedure was used based on the regression
method. Considering the scores obtained, we explored
their usefulness in differentiating the patients according
to external criteria, based on t-tests between extreme
groups of patients (first quartile versus the fourth quar-
tile), along with the usefulness of the ICAF. The SPSS
statistical package was used throughout.
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Questionnaires analysis
FIQ
An exploratory factor analysis with a Kaiser-Meyer-
Olkin (KMO) index of 0.83, yielding two factors that
explained 57% of the variance. The first explains 44% of
the variance and groups the items 1, 3, 4, 6-8, relating
to patient activities and energy. Items 1, 3 and 8 were
excluded due to low correlation with the scale. The sec-
ond factor (12%) was excluded, since it evaluates anxi-
ety, depression and pain intensity, which are evaluated
by other questionnaires.
HADs
The anxiety scale was reduced by four items, those with
a lesser correlation with the scale (items 6, 8, 10 and
14), thereby leaving items 2, 4 and12. The same was
applied to the depression scale, excluding items 3, 7, 9
and 11, and leaving items 1, 5, and 13.
BPI
The pain measurement scale was considered, discarding
the item conforming the scale relating to pain interference
with patient daily life, since these were evaluated by other
questionnaires. Items 1 and 4 were excluded due to the
low correlation with the scale. Items 2 and 3 were accepted.
FAS
An exploratory factor analysis yielded three factors. This
contrasts with the original report on the scale [10],
which only cited one factor. In our study, with a KMO
of 0.882, these three factors explained 69.6% of the var-
iance. The first factor (48.4%) is referred to as physical
fatigue, with the involvement of items 1-3, 5 and 6. This
was the only factor considered in our study.
HAQ
We considered the 8 items referred as FHAQ [29]
(items 1, 3, 10, 13, 14, 18-20). Items 3, 14 and 18
showed a low correlation with the scale and were
rejected. Items 1, 10, 13, 19 and 20 were accepted.
GHQ-28
We considered the four scales forming the question-
naire, excluding the first (somatisation scale; items 1-7).
F i v ef a c t o r sw e r eo b t a i n e d .T h el a s tt w ow i t hal e s s e r
eigenvalue (1.28 and 1.08% of the variance) corre-
sponded to items 1 to 7, yielding two small factors of
the original somatisation scale. These items were there-
fore excluded. In sum, we considered three scales: anxi-
ety (8-14), social dysfunction (15-21) and depression
(22-28). We excluded several items due to their low cor-
relation with the scale, and the items accepted were:
anxiety (10, 11, 13 and 14), social dysfunction (17, 18
and 21) and depression (24, 25, 27 and 28).
CPCI
An exploratory factor analysis yielded 14 factors. Based
on the relevant analysis, the following factors and items
were finally considered: coping (14, 23, 27, 49), task per-
sistence (4, 28, 34, 51, 63), relaxation (1, 12, 59), asking
for assistance and seeking social support (9, 16, 44, 57),
avoidance (15, 33, 41, 42) and resting (47, 58).
ASES
We eliminated four items corresponding to those exhi-
biting a lesser correlation with the scale. Items 1, 2, 6
and 7 were thus considered.
SQS
The only item of this scale was included.
Construction of the Combined Index of Severity of
Fibromyalgia (ICAF)
An exploratory factor analysis was made involving the
scales resulting from item reduction indicated in the
section above. With a KMO of 0.86, four factors
explaining 64% of the variance were obtained (table 1).
The first factor was referred to as Emotional, and
accounted for 33.7% of the variance. The emotional
aspects relating to anxiety, depression and related social
elements are involved in this factor. The second factor
was referred to as Physical-Activity, and explains 15% of
the variance. It covers the physical aspects of the syn-
drome: pain, fatigue, sleep quality and functional capa-
city. The third factor was referred to as Active Coping,
and explains 9% of the variance. It covers positive strate-
gies for coping with the syndrome, involving an active
position on the part of the patient, and moreover
includes positive expectations of self-efficacy related
with the disease. Finally, the fourth factor was referred
to as Passive Coping, and explains 6.3% of the variance.
It addresses ways of coping with the disease centered on
inactivity and on the asking for external support.
We thus considered four scales that address the basic
elements of the disease: the emotional aspects, which
explain most of the variance (a little over 50%); the prin-
cipally physical aspects, which account for a quarter of
the variance; and the third and fourth scales, that
address coping strategies. Two coping categories were
obtained: a positive category, referred to as Active, since
it contributes to improve the clinical condition through
active improved self-efficacy measures; and a negative
category that explains a lesser proportion of the variance
and seeks to resolve the problems through passivity and
by resorting to others.
The Emotional Factor comprises 17 items and yields
reliability as determined by Cronbach’s alpha of 0.93. Phy-
sical-Activity comprises 16 items and yields a Cronbach’s
alpha of 0.88. Active Coping comprises 16 items with a
Cronbach’s alpha of 0.85. Finally, Passive Coping comprises
10 items with a Cronbach’s alpha of 0.7. A tool composed
of four scales and a total of 59 items is thus formed.
Scores in the ICAF indexes are shown in Table 2. We
used T scores to standardize and to facilitate the
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between 20 to 80.
We used a total of 59 items from 9 instruments. Con-
sidering that the new instrument is in part built with
this questionnaires, may be questionable to correlate
this new instrument with those that were used to create
it. Table 3 shows these correlations.
Utility of the Combined Index of Severity of Fibromyalgia
(ICAF)
Comparison was made of the patients not on sick leave
versus those temporarily or permanently off work. Com-
parisons were also made of the extreme groups, quartile
1 and quartile 4, corresponding to the following vari-
ables: MUSs, number of tender points, the results of the
6-MWT, patient comorbidity, and the total cost of the
disease. We also compared these comparisons with FIQ
scores, to observe the differences with ICAF indexes.
The results can be seen in table 4. The descriptive sta-
tistics of the sample for ICAF have been omitted, as
these are standardized factor scores.
Discussion
This study offers a tool allowing more complete and
rapid evaluation of fibromyalgia patients. The test intrin-
sically evaluates emotional aspects: anxiety and depres-
sion, and their impact upon social aspects. It also
evaluates pain, fatigue, sleep quality, functional capacity
and the way in which the patient copes with the disease.
This is achieved by means of a self-assessment question-
naire based on elements from well known tests. The
ICAF comprises four scales that offer differential infor-
mation on the different aspects of the disorder. The
most important scale is the so-called Emotional Factor,
which generates a little over 50% of the information of
the test. This stresses the role of emotional aspects
(anxiety and depression) in fibromyalgia syndrome.
Similar findings have been reported by other authors
[30]; using the Structured Clinical Interview for DSM-IV
(SCID I and II), they recorded anxiety symptoms for
32.2% of the patients, and depression in 34.8%. The
patients evaluated in this study yielded a higher score
for this factor when on sick leave, with increased
comorbidity, a larger number of MUSs, and when the
health care expenditure was higher. This Emotional Fac-
tor allows us to discriminate the patients in which fibro-
myalgia is more severe due to a greater social and
occupational impact, and a greater variety in the
Table 1 Exploratory factor analysis; factor loadings by
instruments used.
Factors
I
Emotional
II
Physical-
Activity
III
Active
Coping
IV
Passive
Coping
HADs_ANX_short .707 .258 -.301 .187
HADs_DEPRE_short .799 .176 -.083 .057
GHQ_ANX_SLEEP_short .838 .197 -.025 -.049
GHQ_SOCIAL_DISF_short .690 .205 -.142 .080
GHQ_DEPRE_short .749 .114 -.228 .155
SQS .151 .683 .050 -.178
FIQ_short .243 .767 .012 .298
FHAQ_short .312 .565 -.080 .411
FAS_PHYSICAL .283 .603 -.129 .394
BPI_PAIN_short .147 .720 -.025 .093
ASES_short -.283 -.154 .549 -.223
Coping -.190 .113 .800 .141
Persistence -.045 -.125 .741 -.136
Relaxation -.082 .101 .758 .270
External_Support .004 -.062 .117 .664
Avoidance .141 .381 .017 .671
Resting .086 .124 -.058 .637
Key: Factor loadings by each group of items. HADs_ANX_short: items 2,4,12
from the Hospital Anxiety and Depression Scales, HADs_DEPRE_short: 1,5,13,
GHQ_ANX_SLEEP_short: 10,11,13,14 from the Goldberg Health Questionnaire-
28, GHQ_SOCIAL_DISF_short: 17,18,21, GHQ_DEPRE_short: 24,25,27,28, SQS:
Scale of Quality of Sleep, FIQ_short: 4,6,7 from Fibromyalgia Impact
Questionnaire, FHAQ_short: 1,10,13,19,20 from the Health Assessment
Questionnaire, FAS_PHYSICAL: 1,3,5,6 from the Fatigue Assessment Scale,
BPI_PAIN_short: 2,3 from the Brief Pain Inventory, ASES_short: 1,2,6,7 from the
Arthritis Self-Efficacy Scale, Coping: 14,23,27,49 from the Chronic Pain Coping
Inventory, Persistence: 4, 28,34,51,63, Relaxation: 1,12,59, External_Support:
9,16,44,57, Avoidance: 15,33,41, 42, Resting: 47,58
Table 2 Scores of the ICAF indexes.
N = 301 Total Emotional Physical Active Coping Passive Coping
Range 47.19 44.85 49.89 49.08 47.95
Minimum 26.63 31.07 20.44 25.04 24.91
Maximum 72.82 75.92 70.33 74.13 72.86
Percentile
25 42.53 42.04 43.52 42.51 42.98
50 50 50 50 50 50
75 56.70 56.80 56.92 57.48 56.88
Key: T scores (mean = 50, sd = 10). Total = general score including all the four factors. Emotional = score in the emotional factor, Physical: score in the physical
factor, Active Coping: score in the active coping factor, Passive Coping: score in the passive coping factor
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of emotional factors upon worsening of the disorder has
been observed by other investigators in relation to dif-
ferent aspects ranging from coping with the disease [5]
to its neuropsychological effects [31].
The second scale of the ICAF is the so-called Physi-
cal-Activity scale, which evaluates pain, fatigue, sleep
quality and functional capacity, included in the main
clinical domains of fibromyalgia suggested by other
authors [32]. It is quantitatively less important than the
Emotional Factor, but is also clearly differentiated from
the latter. In relation to the external measures obtained,
this scale has been shown to be sensitive to the number
of tender points, the results of the 6-MWT, and the sick
leave in occupationally active patients. It is also sensitive
to resource expenditure. Specificity therefore exists in
two physical aspects: the number of tender points and
the distance covered in the 6-MWT. Our findings are in
agreement with those of other authors who underscore
the usefulness of the number of tender points and their
clinical relevance [33-35], as well as with those who
relate them to pain intensity and disability [35].
The third and fourth ICAF scales are quantitatively of
little importance, though they are nevertheless of special
clinical interest. The Active Coping scale is a protective
factor, since it includes positive coping strategies,
together with increased self-efficacy. Although no statis-
tically significant differences were found among the stu-
died variables, this trend as a positive factor was
confirmed. Lastly, the Passive Coping scale allows us to
identify a group of particularly severely affected patients.
In addition to underscoring the aspects relating to sick
leave, the MUSs, number of tender points and poorer
performance in the 6-MWT also have an impact. A
recent study [36] found that the existence of activities
associated to pain symptoms, and which may be
regarded as coping strategies, is related to the amount
of self-reported physical activity.
A particularly relevant aspect of this study is that the
criteria chosen for demonstrating the usefulness of the
ICAF are independent from the aspects evaluated by the
questionnaires, and moreover have been obtained objec-
tively, establishing contrasts with the patient case his-
tories in all cases. Based on the results obtained in our
study, and adopting the caution required in generalizing
the findings, the ICAF can provide an orientation as to
the usefulness of administering the mentioned tests,
with a view to securing adequate patient assessment in
these aspects.
Today the main reference to evaluate the fibromyalgia
impact is the FIQ, but this questionnaire only offers a
global score. This score would not to be sufficient to
Table 3 Correlations between ICAF indexes and several instruments.
N = 301 Total Emotional Physical Active Coping Passive Coping
FIQ .686** .429** .662** -.048 .329**
FAS .558** .414** .516** -.185** .370**
BPI .615** .335** .739** -.095 .251**
HAQ .593** .331** .501** -.093 .447**
HADs anxiety .472** .795** .180** -.096 .064
HADs depression .463** .722** .254** -.314** .263**
CPCI .697** -.021 .143* .715** .556**
GHQ-28 .559** .862** .295** -.121* .083
ASES -.086 -.244** -.129* .504** -.304**
Key: ** p < .01, * p < .05
Table 4 Mean differences in factor scores of several patients groups.
Mean differences in factor scores Mean diff.
Emotional Physical-Activity Active Coping Passive Coping Total FIQ
No sick leave vs temporary leave N(170/42) -.405* -.236 .234 -.287 -.646* -6,433**
No sick leave vs permanent leave N(170/35) -.725** -.493* .127 -.368* -1.546** -10.114**
Workers. No sick leave vs temporary leave N(94/37) -.440* -.289 .298 -.352 -.773* -7.491**
MUSs. 1Q vs 4Q N(81/81) -.490* -.161 .098 -.473* -1.007** -6.022**
Number of tender points. 1Q vs 4Q N(111/87) -.172 -.496** -.157 -.318* -1.196** -6.908**
Six-minutes walk test. 1Q vs 4Q N(32/73) .348 .526* -.229 .811** 1.346** 6.290**
Comorbidity. 1Q vs 4Q N(74/107) -.486** -.116 .204 -.122 -.548 -3.401
Total cost 1Q vs 4Q N(67/72) -.603** -.762** .213 -.585** -1.757** -11.957**
Key: *p < .05, **p < .01, MUSs = medically unexplained syndromes,1Q = 1
st quartile, 4Q = 4
th quartile
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patients. In table 4, we can see that the FIQ and ICAF
global offer similar information in number of tender
points, medically unexplained syndromes, six-minutes
walk test, and several sick leave comparisons. But the
ICAF scales offer valuable additional information. In the
case of the MUSs (e.g.), the difference is located in the
emotional factor and in the passive coping factor, but
not in the physical component of the ICAF. In the vari-
able of comorbidity neither the global index FIQ nor
the ICAF show a statistical significant difference, but the
ICAF emotional factor discriminates in this variable.
The ICAF instrument is longer than FIQ, but it allows
to access to more complete information that could be
useful to discriminate some patients or the effect of
diverse therapeutical modalities commonly used in this
syndrome: pharmacological, psychopharmacological,
physical or psychological.
The structure of the ICAF, and its items, are derived
from items of well known and scientifically solid tools.
This serves to ensure maximum validity and reliability
of the results obtained, and constitutes a safe starting
point for examining the usefulness of the tool. On the
other hand, the tool includes the main evaluative
domains considered to be of importance in fibromyalgia.
Some domains such as sexual activity may be considered
lacking, though this has not been clearly confirmed [17].
The evaluation of cognitive alterations and dysfunctions
has not been included, due to their lesser importance
and the lack of tools adjusted to our setting - though
this aspect requires due examination in future studies.
We likewise used no generic quality of life question-
naire, since it is considered that the usual components
of such questionnaires have been sufficiently evaluated.
The sample of this study consists of 291 women and
10 men. This proportion reflects the ratio between
women and men commonly found tine population with
fibromyalgia syndrome. However, in order to control for
the sex variable we also carried out an analysis with a
sample including women only. The results were similar
to the ones obtained with the mixed sample (data not
shown).
T h eI C A Fm u s tb ee x a m i n e db yf u t u r es t u d i e si n v o l -
ving other samples, in order to confirm the factor struc-
ture obtained its test-retest reliability and sensitivity to
change, with a view to more extensive evaluation of its
usefulness as an index of the severity of fibromyalgia.
Conclusions
This exploratory study offers a tool allowing more com-
plete and rapid evaluation of patients with fibromyalgia.
The test intrinsically evaluates the emotional aspects:
anxiety and depression, and their impact upon social
aspects. It also evaluates patient functional capacity,
fatigue, sleep quality, pain, and the way in which the
patient copes with the disease. This is achieved by
means of a self-assessment questionnaire based on ele-
ments from well known tests. Despite to the limitations
discussed above the four factor structure obtained is an
interesting tool to clarify the clinical aspects of the
fibromyalgia syndrome. A test-retest reliability and
validity (confirmatory factorial analysis) with other
patients samples are needed to explore the clinical uti-
lity of the ICAF.
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de Afectación de la Fibromialgia) of the English “Com-
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